Goodwin Procter LLP

Please note: The information displayed on this page might be outdated.
Goodwin Procter LLP: Goodwin is a leading law firm, with a team of more than 1,000 attorneys serving clients across the globe. Goodwin boasts a dynamic Life Sciences practice servicing the needs of the biotech, pharma, and healthcare industries in key life sciences hubs. The team is deeply experienced in developing and implementing creative strategies to help maximize the value and position of our clients across all phases of the corporate life cycle including on corporate, intellectual property, FDA/regulatory, and litigation matters. Since the beginning of 2018, Goodwin advised issuers on more than a twenty biotechnology and pharmaceutical industry IPOs worth in aggregate nearly $3 billion — making Goodwin the number one advisor in this sector by offering value. To learn more, visit us at http://www.goodwinlaw.com and follow us on Twitter, LinkedIn and Instagram.
Sector/Industry:
Service Provider
Characteristics:
Based in...
US - New England
Listing
Private
Website:
Address:
100 Northern Avenue
Boston, MA 02210
United States

Company Participants at 2020 Wall Street "On Tap"

Edwin O'Connor
Goodwin Procter LLP, Partner
Edwin O’Connor, a partner in Goodwin’s Technology Companies Group, has a broad-based capital markets practice and represents issuers and underwriters in public and private corporate finance transactions, both in the United States and internationally. His experience encompasses initial public offerings, follow-on equity offerings, investment grade, high-yield and convertible debt offerings and offerings of preferred, hybrid and derivative securities. He has particular experience with capital markets transactions in the tech, life sciences and clean tech sectors.
Jocelyn Arel
Goodwin Procter LLP, Partner
Jocelyn Arel is a pioneer in the U.S. for her innovative work for clients on SPACs, with nearly two decades of successful SPACs transactions under her belt. Ms. Arel advises clients in all aspects of the SPAC lifecycle, including the formation and structuring sponsor entities, representing SPACs and SPAC sponsors in initial public offerings (“IPOs”); representing operating companies, their investors and SPACs in business combinations, or “SIPO transactions”; structuring the debt and equity financing transactions that are often needed to facilitate the closing of SIPO transactions; and, advising investors in both SPAC IPOs and SIPO transactions. In addition to her extensive knowledge of the legal issues related to SPACs, Ms. Arel has a deep understanding of the business, financial and marketing issues that affect the success of SPACs. In addition to her leadership in the SPAC market, Ms. Arel represents clients in a wide range of capital market transactions, including initial and follow-on public offerings, private placements of debt and equity, alternative financing and 144A transactions, mergers and acquisitions and joint ventures. She has extensive experience in cross-border financings and acquisitions, as well as in providing advice on other U.S.-based activities for companies headquartered in Canada. A significant portion of Ms. Arel’s practice includes counseling clients on ongoing reporting requirements of public companies, corporate governance matters and various other matters affecting public companies, their officers and directors. She also has considerable expertise in structuring and executing secondary sales and other private liquidity programs for private companies and their investors.
Markus Bauman
Goodwin Procter LLP, Head of European Strategic Relations
Markus Bauman is a partner in Goodwin’s Technology and Life Sciences group. Mr. Bauman specializes in corporate finance, including equity and debt offerings, and mergers and acquisitions. He represents emerging growth companies, public companies, investment banks, investors, financial sponsors and other market participants in both public and private cross-border transactions. Mr. Bauman assists clients in a variety of equity and debt offerings, including U.S.-registered and 144A/Reg. S, initial public offerings, initial coin offerings, private placements, and investment grade and high-yield bonds. He has advised on financings on every major stock exchange in Europe. He also advises clients on U.S. securities laws, mergers and acquisitions, corporate governance and compliance. Prior to joining Goodwin in 2017, Mr. Bauman worked at international law firms and as Executive Director of the Investment Banking Division Legal department of Goldman Sachs International. Mr. Bauman also completed a secondment in the Debt Capital Markets Legal department of J.P. Morgan in London. Mr. Bauman is a fluent German speaker and is proficient in Italian.
Robert Puopolo
Goodwin Procter LLP, Partner
Rob Puopolo, a partner in Goodwin’s Life Sciences practice, focuses his practice on representing public and privately held life sciences companies, as well as the venture capital firms, hedge funds and investment banks that focus on these companies.